WithdrawnPhase 2Phase 3ACTRN12605000153617
The role of Dipyridamole in Improving the False Negative Rate in Pre-Operative Parathyroid Adenoma Localisation Using 99mTc Sestamibi
Sponsor
Robert Williams
Enrollment
20 participants
Start Date
Dec 11, 2005
Study Type
Interventional
Conditions
Eligibility
Sex: Both males and femalesMin Age: 18 Yearss
Inclusion Criteria1
- Previous negative 99mTc Sestamibi parathyroid scan. No subsequent parathyroid surgery. Abnormal parathyroid Hormone (PTH ) levels. Strong clinical suspicion of parathyroid adenoma. Permission of referring doctor. Informed consent of patient.
Exclusion Criteria1
- Age younger than 18 years, pregnancy, unable to gain informed consent, unstable cardiac disease, Asthma, hypotension, hypersensitivity to aspirin or dipyridamole.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The use of Dipyridamole in Improving the False Negative Rate in Pre-Operative Parathyroid Adenoma Localisation Using 99mTc Sestamibi.
Dipyridamole is used to enhance the uptake of Tc99m-Sestamibi in
The use of Dipyridamole in Improving the False Negative Rate in Pre-Operative Parathyroid Adenoma Localisation Using 99mTc Sestamibi. Dipyridamole is used to enhance the uptake of Tc99m-Sestamibi in repeat parathyroid imaging.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000153617